SMALL CELL CARCINOMA OF ANY OTHER ORIGIN

Clinical trials for SMALL CELL CARCINOMA OF ANY OTHER ORIGIN explained in plain language.

Never miss a new study

Get alerted when new SMALL CELL CARCINOMA OF ANY OTHER ORIGIN trials appear

Sign up with your email to follow new studies for SMALL CELL CARCINOMA OF ANY OTHER ORIGIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial

Disease control Recruiting now

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …

Matched conditions: SMALL CELL CARCINOMA OF ANY OTHER ORIGIN

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

SMALL CELL CARCINOMA OF ANY OTHER ORIGIN

Get alerted when new SMALL CELL CARCINOMA OF ANY OTHER ORIGIN trials appear

New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial